Lung Cancer
From the Journals
Lung screening complications costly, more prevalent than in trial setting
Patients and physicians should be discussing the potential harms and downstream costs in shared decision-making visits.
From the Journals
More benefit to chemoradiation in earlier small cell lung cancer
While unsurprising, the findings provide an early disease benchmark for safety and efficacy.
From the Journals
Frontline veliparib/cisplatin/etoposide shows efficacy in advanced SCLC
Adding the PARP inhibitor to standard frontline chemotherapy offered a slight PFS benefit but no overall survival benefit.
From the Journals
ICYMI: Durvalumab boosts overall survival in stage III NSCLC
The median overall survival was 12 months greater in those receiving durvalumab, compared with those receiving placebo.
From the Journals
Perioperative M&M similar for lobar, sublobar surgeries in early lung cancer
Though disease-free survival results are still pending, mortality and adverse effects were similar at 30 and 90 days.
News
Atezolizumab combination regimen approved for advanced non-squamous NSCLC
The FDA approved checkpoint inhibitor atezolizumab for the treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor...
Conference Coverage
Lenvatinib/Pembrolizumab shows promise in previously treated metastatic NSCLC
WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and...
News from the FDA/CDC
Cigarette smoking at lowest level ever
Prevalence dropped to 14% among adults in 2017, but control strategies need to “address the diversity of tobacco products.”
News
FDA approves lorlatinib as second line for ALK-positive advanced NSCLC
The approval was based on an overall response rate of 48% in patients previously treated with one or more ALK kinase inhibitors.
News
FDA expands approval of pembrolizumab in NSCLC
Pembrolizumab is now approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of...